Phase I Study of Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction for Inoperable Primary or Metastatic Carcinoma (SMART ONE)
Summary
The purpose of this study is to evaluate the safety and feasibility of single- fraction of SMART (Stereotactic magnetic resonance (MR) guided adaptive radiation therapy) in patients with solid tumors, including pancreatic cancer.
General Information
NCT#: NCT04939246
Study ID: 2020-CHU-002
Trial Phase: Phase I
Trial Sponsor: Viewray Inc., Baptist Health South Florida
Therapies Used in This Trial: Stereotactic Ablative Radiotherapy (SABR)